Mechanisms of action of low molecular weight heparins and heparinoids.
Ofosu
F A
FA
Barrowcliffe
T W
TW
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D001798:Blood Proteins / Q000378:metabolism; D002240:Carbohydrate Sequence; D004195:Disease Models, Animal; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D006496:Heparinoids / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D011485:Protein Binding; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000188:drug therapy
D001798:Blood Proteins; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D000990:Antithrombin III; D013917:Thrombin